---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-018724"
form_type: "8-K"
ticker: "ADGM"
cik: "0002006986"
company_name: "Adagio Medical Holdings, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-26T00:17:56.479474+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adagio Medical restructures to focus on US pivotal IDE trial; reduces workforce

## Summary
- Pauses limited European launch of vCLAS catheter; redirects resources to US FULCRUM-VT Pivotal IDE trial (over 35% enrolled).
- Reduction in force effective February 28, 2025, to enable additional investment in clinical trial and product design optimization.
- Streamlining operations and realigning resources toward US FDA premarket approval for VT Cryoablation System with vCLAS catheter.
- CEO Todd Usen cites broad applicability of ultra-low temperature cryoablation technology and aim to lead ventricular tachycardia market.

## SEC filing metadata
- accession: 0001104659-25-018724
- form_type: 8-K
- ticker: ADGM
- cik: 0002006986
- company_name: Adagio Medical Holdings, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006986/000110465925018724/0001104659-25-018724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006986/000110465925018724/tm257750d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-018724
- JSON: https://secwatch.observer/filing/0001104659-25-018724.json
- Plain text: https://secwatch.observer/filing/0001104659-25-018724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.